Adimab, Inc. has entered into a research collaboration in which it will use its discovery platform to identify fully human antibodies against two targets selected by Novartis. Novartis has rights to commercialize antibodies generated from the collaboration. Adimab will receive upfront payments, preclinical milestones and licensing fees and is also eligible to receive development milestones and royalties on therapeutic and diagnostic product sales. “Most pharma companies currently have access ...